Amycretin

An experimental single molecule from Novo Nordisk that acts on both GLP-1 and amylin receptors, tested as a weekly shot and a daily pill.

Evidence: Ongoing clinical research
Half-life: Days
Sources: 2 cited

Is amycretin FDA-approved?

Investigational. Not FDA-approved.

Overview

Amycretin combines the GLP-1 and amylin fullness signals in one molecule. In an early phase 1b/2a trial of the weekly shot, weight loss at 36 weeks was about 22–24% on the higher doses, versus roughly no change on placebo. These were small trials with many dropouts, and larger trials are underway.

How it works

One molecule switches on both GLP-1 receptors (appetite, insulin, stomach emptying) and amylin receptors (fullness), similar to taking CagriSema as a single drug.

How long does amycretin stay in the body?

Long enough for once-weekly shots in trials; a daily pill version is also being tested.

What it's studied for

Obesity
Type 2 diabetes

Reported side effects

Nausea, vomiting, diarrhea (mostly mild to moderate)

Sources

The studies and prescribing labels this page is written from.